← Eichor
Study identifier: NCT06445114 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Condition: Oropharyngeal Cancer · Carcinoma  ·  Sponsor: Zachary Zumsteg

PhasePhase 2
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trial Navigator  ·  3104232133  ·  GroupCancerTrialInformation@cshs.org

Always discuss trial participation with your own doctor first.

Locations (4)

Cedars-Sinai Cancer at Beverly Hills (THO)Beverly Hills, California, United StatesRecruiting
Cedars Sinai Medical CenterLos Angeles, California, United StatesRecruiting
CS Cancer at Valley Oncology Medical GroupTarzana, California, United StatesRecruiting
CS Cancer at the Hunt Cancer CenterTorrance, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06445114